HK1204267A1 - Method of enhancing efficacy of blood transfusions - Google Patents

Method of enhancing efficacy of blood transfusions Download PDF

Info

Publication number
HK1204267A1
HK1204267A1 HK15104771.0A HK15104771A HK1204267A1 HK 1204267 A1 HK1204267 A1 HK 1204267A1 HK 15104771 A HK15104771 A HK 15104771A HK 1204267 A1 HK1204267 A1 HK 1204267A1
Authority
HK
Hong Kong
Prior art keywords
blood transfusions
enhancing efficacy
efficacy
blood
subject
Prior art date
Application number
HK15104771.0A
Other languages
English (en)
Chinese (zh)
Inventor
Seetharama A. Acharya
Marcos Intaglietta
Original Assignee
Albert Einstein College Of Medicine Of Yeshiva University
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine Of Yeshiva University, The Regents Of The University Of California filed Critical Albert Einstein College Of Medicine Of Yeshiva University
Publication of HK1204267A1 publication Critical patent/HK1204267A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK15104771.0A 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions HK1204267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
US61/613,105 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (1)

Publication Number Publication Date
HK1204267A1 true HK1204267A1 (en) 2015-11-13

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104771.0A HK1204267A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Country Status (10)

Country Link
US (2) US8859499B2 (cs)
EP (1) EP2827887A4 (cs)
JP (1) JP2015515462A (cs)
BR (1) BR112014023200A2 (cs)
CL (1) CL2014002464A1 (cs)
HK (1) HK1204267A1 (cs)
IN (1) IN2014MN02089A (cs)
MX (1) MX2014011186A (cs)
WO (1) WO2013142135A1 (cs)
ZA (1) ZA201407616B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
IN2014MN02089A (cs) 2012-03-20 2015-09-11 Einstein Coll Med
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EA035336B1 (ru) 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способ лечения связанного со старением когнитивного расстройства или заболевания
EP3218011A4 (en) * 2014-11-14 2018-06-27 Aima Biotech Conjugated proteins
US20170258937A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
TW202417036A (zh) 2015-05-28 2024-05-01 法商奈諾生技公司 作為治療疫苗之奈米顆粒
DK3307296T3 (da) 2015-06-15 2021-12-13 Univ Leland Stanford Junior Timp2 til anvendelse til behandling af aldringsassocierede tilstande
WO2017083281A1 (en) * 2015-11-09 2017-05-18 Albert Einstein College Of Medicine, Inc. Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
ES3037703T3 (en) 2016-04-28 2025-10-06 Alkahest Inc Blood plasma and plasma fractions as therapy for tumor growth and progression
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
AU2018257921B2 (en) 2017-04-26 2024-06-06 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2019018403A1 (en) 2017-07-18 2019-01-24 Virtech Bio, Llc BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING
UA128648C2 (uk) 2018-10-26 2024-09-18 Алкахест, Інк. Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення
JP7773169B2 (ja) * 2021-02-24 2025-11-19 学校法人 中央大学 ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
AU752037B2 (en) * 1997-09-26 2002-09-05 Uab Research Foundation Reduced antigenic cells and uses therefor
EP1115414B1 (en) * 1998-09-25 2003-12-17 Oklahoma Medical Research Foundation Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
WO2001034648A1 (en) * 1999-11-12 2001-05-17 Baxter International, Inc. Reduced side-effect hemoglobin compositions
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
EP1819330A1 (en) * 2004-12-01 2007-08-22 Devgen N.V. 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
WO2006135740A1 (en) 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
EP2391341A4 (en) * 2009-01-30 2012-05-09 Cuthbert O Simpkins REVIVAL LIQUID
US8815297B2 (en) * 2009-03-31 2014-08-26 Duke University Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
US20130231287A1 (en) * 2010-02-25 2013-09-05 Parimala Nacharaju Pegylated albumin polymers and uses thereof
IN2014MN02089A (cs) 2012-03-20 2015-09-11 Einstein Coll Med
EP3218011A4 (en) 2014-11-14 2018-06-27 Aima Biotech Conjugated proteins

Also Published As

Publication number Publication date
EP2827887A4 (en) 2016-04-20
US20150017146A1 (en) 2015-01-15
BR112014023200A2 (pt) 2018-09-18
CL2014002464A1 (es) 2015-08-28
US20130261061A1 (en) 2013-10-03
MX2014011186A (es) 2015-03-06
WO2013142135A1 (en) 2013-09-26
IN2014MN02089A (cs) 2015-09-11
US8859499B2 (en) 2014-10-14
US9498537B2 (en) 2016-11-22
JP2015515462A (ja) 2015-05-28
ZA201407616B (en) 2016-08-31
EP2827887A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
HK1204267A1 (en) Method of enhancing efficacy of blood transfusions
HK1258697A1 (zh) 乙肝核心蛋白調節劑
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
EP2702994A3 (en) Methods of administering pirfenidone therapy
HK1204578A1 (en) Medicament for the treatment of acute myeloid leukemia (aml)
WO2014068475A3 (fr) Dispositif de traitement extra corporel du sang
HK1198869A1 (en) Combination treatments for hepatitis c
WO2013117744A3 (en) Methods of treating fibrosis
WO2013106689A8 (en) Hcv ns3 protease inhibitors
WO2015084741A3 (en) Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2012158437A3 (en) Cannula apparatus and ventricular assist systems using the cannula apparatus
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
EP2994134A4 (en) Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
CA3010788A1 (en) Methods of administering vasopressors
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
HK1209051A1 (en) A method of improving liver function
CA2893036C (en) Uses of bacopa monnieri extract
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
HK1209041A1 (en) A method of weight reduction
EA201492161A1 (ru) N-метил-4-бензилкарбамидопиридиний хлорид и способ его получения
WO2014075033A3 (en) Protein stabilizing factors
HK1220133A1 (zh) 改善微血管完整性的方法